Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more
Sartorius Stedim Biotech S.A (SDMHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.059x
Based on the latest financial reports, Sartorius Stedim Biotech S.A (SDMHF) has a cash flow conversion efficiency ratio of 0.059x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($242.51 Million) by net assets ($4.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sartorius Stedim Biotech S.A - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sartorius Stedim Biotech S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sartorius Stedim Biotech S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
F.N.B. Corp
NYSE:FNB
|
0.019x |
|
PT Astra International Tbk
PINK:PTAIF
|
0.035x |
|
Guangdong Haid Group Co Ltd
SHE:002311
|
0.076x |
|
TERRENO REALTY DL -01
F:T37
|
N/A |
|
MGIC Investment Corp
NYSE:MTG
|
0.042x |
|
China Oilfield Services Ltd Class A
SHG:601808
|
0.052x |
|
Churchill Downs Incorporated
NASDAQ:CHDN
|
0.091x |
|
Amkor Technology Inc
NASDAQ:AMKR
|
0.143x |
Annual Cash Flow Conversion Efficiency for Sartorius Stedim Biotech S.A (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sartorius Stedim Biotech S.A from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.12 Billion | $538.40 Million | 0.131x | -35.56% |
| 2024-12-31 | $4.02 Billion | $815.10 Million | 0.203x | -27.45% |
| 2023-12-31 | $2.67 Billion | $746.40 Million | 0.279x | +14.65% |
| 2022-12-31 | $2.51 Billion | $612.30 Million | 0.244x | -39.35% |
| 2021-12-31 | $1.73 Billion | $695.97 Million | 0.402x | +42.84% |
| 2020-12-31 | $1.48 Billion | $416.88 Million | 0.281x | +6.75% |
| 2019-12-31 | $1.18 Billion | $310.13 Million | 0.263x | +21.07% |
| 2018-12-31 | $1.04 Billion | $227.29 Million | 0.218x | +9.51% |
| 2017-12-31 | $879.45 Million | $174.69 Million | 0.199x | -3.19% |
| 2016-12-31 | $763.56 Million | $156.66 Million | 0.205x | -7.00% |
| 2015-12-31 | $647.22 Million | $142.79 Million | 0.221x | +6.73% |
| 2014-12-31 | $538.51 Million | $111.31 Million | 0.207x | +10.53% |
| 2013-12-31 | $481.84 Million | $90.11 Million | 0.187x | +66.16% |
| 2012-12-31 | $434.72 Million | $48.93 Million | 0.113x | -26.52% |
| 2011-12-31 | $395.63 Million | $60.59 Million | 0.153x | -23.15% |
| 2010-12-31 | $365.07 Million | $72.76 Million | 0.199x | -14.69% |
| 2009-12-31 | $393.20 Million | $91.86 Million | 0.234x | +83.84% |
| 2008-12-31 | $371.65 Million | $47.23 Million | 0.127x | +77.15% |
| 2007-12-31 | $362.76 Million | $26.02 Million | 0.072x | -76.57% |
| 2006-12-31 | $168.93 Million | $51.72 Million | 0.306x | +3.56% |
| 2005-12-31 | $148.35 Million | $43.85 Million | 0.296x | -- |